Author of

• 34876

  +

  P02 - Diagnostics and Interventional Pulmonology (ID 110)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Diagnostics and Interventional Pulmonology
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 34905

    +

    P02.24 - Liquid Biopsy Mutation Profiling in Non-Small Cell Lung Cancer (ID 2359)

    00:00 - 00:00  |  Presenting Author(s): Vaida Gedvilaitė
    • Abstract
    • Slides

    Introduction
    

    Non-small cell lung cancer (NSCLC) is a common and rapidly progressing cancer with poor survival rates. Analysis of plasma cell-free DNA (cfDNA) overtime could be applied for monitoring of treatment efficiency, relapse and used for cancer molecular profiling. As cfDNA abundancy varies in patients, next-generation sequencing (NGS) is the most efficient and sensitive method to detect mutations from cfDNA.

    Methods
    

    The aim of this study was to screen Lithuanian NSCLC liquid biopsy samples for common lung cancer-related mutations by targeted NGS and to determine their associations with the disease progression.

    Analysis was conducted in plasma samples collected at National Cancer Institute during 2018-2020 before the treatment of NSCLC and after clinical progression. Sequencing libraries were prepared from DNA using Oncomine Lung panel targeting 11 gene 180 hotspot mutation regions

    Results
    

    Out of 39 analysed, in 24 plasma samples taken before treatment we identified 34 protein-coding pathogenic single nucleotide variants (SNV) and 2 small insertions/deletions. Most common pathogenic SNVs in Lithuanian population were KRAS and PIK3CA (14/36 and 10/36, respectively). Mutations were mostly predominant in advanced stage IV NSCLC (20/36) and mutation load increased after clinical progression. Specifically, in serial samples overall mutation burden tended to be higher in patients after treatment vs. paired sample before treatment.

    Conclusion
    

    In conclusion, plasma cfDNA is useful for molecular profiling of NSCLC patients to capture clinically relevant somatic alterations in advanced stage patients and could be used as prognostic biomarker.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.